|Other names||LY-79907; 2-Chloro-6-methylergoline-8β-acetonitrile|
|Chemical and physical data|
|Molar mass||299.80 g·mol−1|
|3D model (JSmol)|
Lergotrile (INN, USAN) is an ergoline derivative which acts as a dopamine receptor agonist. It was developed for the treatment of Parkinson's disease, but failed in clinical trials due to liver toxicity.
- Lieberman AN, Gopinathan G, Estey E, Kupersmith M, Goodgold A, Goldstein M (February 1979). "Lergotrile in Parkinson disease: further studies". Neurology. 29 (2): 267–72. doi:10.1212/wnl.29.2.267. PMID 34808.
- Cunningham KA, Callahan PM, Appel JB (July 1984). "Discriminative stimulus properties of lergotrile". The Journal of Pharmacology and Experimental Therapeutics. 230 (1): 47–52. PMID 6146709.